These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36630728)

  • 1. Clinical course of psoriasis patients that discontinued biologics during the COVID-19 pandemic.
    Topaloğlu Demir F; Polat Ekinci A; Aytekin S; Topkarcı Z; Aslan Kayıran M; Özkök Akbulut T; Oğuz Topal İ; Sarıkaya Solak S; Kara Polat A; Karadağ AS
    J Cosmet Dermatol; 2023 Mar; 22(3):722-731. PubMed ID: 36630728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course.
    Yalici-Armagan B; Tabak GH; Dogan-Gunaydin S; Gulseren D; Akdogan N; Atakan N
    J Cosmet Dermatol; 2021 Oct; 20(10):3098-3102. PubMed ID: 34365714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
    Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
    Warren RB; Gooderham M; Burge R; Zhu B; Amato D; Liu KH; Shrom D; Guo J; Brnabic A; Blauvelt A
    J Am Acad Dermatol; 2020 May; 82(5):1138-1149. PubMed ID: 31884091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
    Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ
    Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
    Kokolakis G; Warren RB; Strober B; Blauvelt A; Puig L; Morita A; Gooderham M; Körber A; Vanvoorden V; Wang M; de Cuyper D; Madden C; Nunez Gomez N; Lebwohl M
    Br J Dermatol; 2023 Feb; 188(3):330-340. PubMed ID: 36751950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register.
    Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
    JAMA Dermatol; 2021 Jan; 157(1):66-73. PubMed ID: 33263718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study.
    Colombo D; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Talamonti M; Megna M; Raspanti M; Paolinelli M; Hansel K; Narcisi A; Conti A; De Simone C; Chessa MA; De Rosa A; Provenzano E; Ortoncelli M; Moltrasio C; Fidanza R; Burlando M; Tonini A; Gaiani FM; Simoni L; Ori A; Fiocchi M; Zagni E
    Dermatol Ther; 2022 Jan; 35(1):e15166. PubMed ID: 34676662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.
    Carrera CG; Dapavo P; Malagoli P; Naldi L; Arancio L; Gaiani F; Egan CG; Di Mercurio M; Cattaneo A
    J Dermatolog Treat; 2018 Aug; 29(5):481-486. PubMed ID: 29058948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry).
    Zitouni J; Bursztejn AC; Belloni Fortina A; Beauchet A; Di Lernia V; Lesiak A; Thomas J; Topkarci Z; Murashkin N; Brzezinski P; Torres T; Chiriac A; Luca C; McPherson T; Akinde M; Maruani A; Epishev R; Vidaurri de la Cruz H; Luna PC; Amy de la Bretêque M; Lasek A; Bourrat E; Bachelerie M; Mallet S; Steff M; Bellissen A; Neri I; Zafiriou E; van den Reek JMPA; Sonkoly E; Mahil SK; Smith CH; Flohr C; Bachelez H; Mahé E;
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2076-2086. PubMed ID: 35748102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.
    Egeberg A; Ottosen MB; Gniadecki R; Broesby-Olsen S; Dam TN; Bryld LE; Rasmussen MK; Skov L
    Br J Dermatol; 2018 Feb; 178(2):509-519. PubMed ID: 29094341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Onset of Action of Biologics in Patients With Moderate-to-Severe Psoriasis.
    Papp KA; Lebwohl MG
    J Drugs Dermatol; 2018 Mar; 17(3):247-250. PubMed ID: 29537442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
    Al-Mutairi N; Nour T
    Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-the BeNeBio study.
    van der Schoot LS; van den Reek JMPA; Grine L; Schots L; Kievit W; Lambert JLW; de Jong EMGJ
    Trials; 2021 Oct; 22(1):707. PubMed ID: 34656148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study.
    Talamonti M; Galluzzo M; Chiricozzi A; Quaglino P; Fabbrocini G; Gisondi P; Marzano AV; Potenza C; Conti A; Parodi A; Piaserico S; Bardazzi F; Argenziano G; Rongioletti F; Stingeni L; Micali G; Loconsole F; Rossi MT; Bongiorno MR; Feliciani C; Rubegni P; Amerio P; Fargnoli MC; Pigatto P; Savoia P; Nisticò SP; Giustini S; Carugno A; Cannavo' SP; Rech G; Prignano F; Offidani A; Lombardo M; Zalaudek I; Bianchi L; Peris K; ; Balestri R ; Bernardini N ; Belloni Fortini A ; Burlando M ; Caldarola G ; Campione E ; Cattaneo A ; Dapavo P ; Dastoli S ; De Simone C ; Di Nuzzo S ; Diotallevi F ; Fierro MT ; Franchi C ; Esposito M ; Foti C ; Gambini DM ; Gambardella A ; Girolomoni G ; Giunta A ; Guarneri C ; Gualdi G ; Hansel K ; Megna M ; Mugheddu C ; Musumeci ML ; Patrizi A ; Pellacani G ; Richetta AG ; Rosi E ; Sacchelli L ; Tiberio R ; Tilotta G ; Trovato E ; Venturini M ; Vezzoni R
    Expert Opin Biol Ther; 2021 Feb; 21(2):271-277. PubMed ID: 33216643
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjunctive Chinese medicine therapy reduces relapse of psoriasis vulgaris after discontinuation of biologics: a prospective registry-based cohort study.
    Huang S; Duan XW; Zhang HC; Dai BW; Bai YP
    J Dermatolog Treat; 2024 Dec; 35(1):2355261. PubMed ID: 38767401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice.
    Calara PS; Norlin JM; Althin R; Carlsson KS; Schmitt-Egenolf M
    BioDrugs; 2016 Apr; 30(2):145-51. PubMed ID: 26883786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents.
    Bronckers IMGJ; Paller AS; West DP; Lara-Corrales I; Tollefson MM; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Blume-Peytavi U; Szalai Z; Vleugels RA; Holland K; Murphy R; Puig L; Cordoro KM; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Seyger MMB;
    JAMA Dermatol; 2020 Apr; 156(4):384-392. PubMed ID: 32022846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial.
    Atalay S; van den Reek JMPA; den Broeder AA; van Vugt LJ; Otero ME; Njoo MD; Mommers JM; Ossenkoppele PM; Koetsier MI; Berends MA; van de Kerkhof PCM; Groenewoud HMM; Kievit W; de Jong EMGJ
    JAMA Dermatol; 2020 Apr; 156(4):393-400. PubMed ID: 32049319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.